Brain Tumor Drug Development Targeting siRNAs

Small interfering RNA (siRNA) is an emerging tool to silence genes that cause disease progression, especially cancer. Compared to existing small molecule and antibody drugs, siRNA drugs have greater potential for development because of their fast target screening, high development success rate, less susceptibility to drug resistance, broader therapeutic area, and long-lasting efficacy. siRNAs are considered a promising drug for the treatment of brain tumors including glioblastoma (GBM).

We offer brain tumor drug development targeting siRNAs

Alfa Cytology offers brain tumor drug development services targeting siRNAs using multiple development strategies and providing clients with diverse development targets. In addition, we are also trying to chemically modify siRNAs to improve their resistance to nuclease degradation and enhance the stability of siRNAs without affecting their efficacy. We can encapsulate siRNA in nano-delivery bodies such as liposomes, inorganic nanocarriers, or polymeric materials such as dendrimers and polymeric micelles to improve siRNA stability. This can effectively avoid the intravascular degradation of siRNA molecules and reduce the potential immunotoxicity of siRNA molecules, which can greatly improve the pharmacokinetic characteristics of siRNA drugs.

Our advantages

• Short development cycle and fast drug target screening. Small molecule and antibody drugs need to recognize the complex spatial conformation of certain proteins and therefore require large-scale drug screening. Our development of siRNA drugs only requires targeting the sequence of the disease-causing gene and designing and synthesizing the corresponding RNA fragment, so their early development is much faster than that of other types of drugs.
• Less susceptible to drug resistance. Since antibodies and small molecules exert their therapeutic effects mainly by regulating cellular signaling pathways and metabolism, drug resistance may develop due to factors such as upregulation of compensatory pathways or decreased antigen expression. In contrast, the siRNA drugs we have developed directly regulate upstream gene expression and are therefore relatively less prone to resistance.
• Broader therapeutic field. Not limited by the druggability of the protein, we can design to target any brain tumor gene of interest, requiring only sequence information of the target mRNA. Promising to attack brain tumor diseases that are still drug-free and difficult to treat.
• Durable effects. The in vivo half-life of small molecule drugs is measured in hours, and the in vivo half-life of antibody drugs is measured in days/weeks. The siRNA drugs we have developed can be recycled multiple times in the body. Therefore, the frequency of drug administration can be reduced and the half-life in vivo can be calculated in months. It has great clinical value for the treatment of chronic brain tumors.
• The success rate of development is high. siRNA drugs have a clear mechanism of action, and we can achieve their functions by completing Watson-Crick base pairing with mRNAs, without the need to fit into the complex structure of proteins.

If you are interested in our services or if you have a unique target for siRNAs development, please feel free to contact us, and the Alfa Cytology team will respond to your questions or assess the feasibility of your proposed target development. We look forward to collaborating with you in this area.